T Cell–Associated Immunotherapy for Hepatocellular Carcinoma

T Cell–Associated Immunotherapy for Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide with limited therapeutic options. Accumulating evidences suggest that immunotherapy could be a promising option for treating HCC. T cell-associated immunotherapy lights up the hope for the improvement of complement...

Full description

Bibliographic Details
Main Authors: Weijie Ma, Long Wu, Fuling Zhou, Zhenfei Hong, Yufeng Yuan, Zhisu Liu
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2017-02-01
Series:Cellular Physiology and Biochemistry
Subjects:
T cellular immunotherapies
Hepatocellular carcinoma
Immune checkpoint blockade
T cell receptor-engineered T cells
Chimeric antigen receptor–engineered T cells
Bispecific T cell engagers
Online Access:http://www.karger.com/Article/FullText/457883

Internet

http://www.karger.com/Article/FullText/457883

Similar Items